GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2022/06/30 15:06:32

Base Information

Drug NameGD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)
Drug Alias Namebi-4SCAR GD2/PSMA T cells Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR GD2/PSMA T cellsGD2/PSMA Bi-specific CAR-T Cellbi-4SCAR GD2/PSMA
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-GD2Anti-PSMA
TargetsDisialoganglioside GD2Prostate-Specific Membrane Antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A